First Choice Neurology

BAN2401

BAN2401 Study to Assess New Alzheimer’s Treatment

If you or a loved one are experiencing signs of early Alzheimer’s disease, there may soon be treatment and hope on the horizon. First Choice Neurology is participating in an FDA-approved Phase III clinical trial to determine the benefit of an experimental product, BAN2401.   What is BAN2401 for Alzheimer’s? BAN2401 is a new class …

BAN2401 Study to Assess New Alzheimer’s Treatment Read More »

BAN2401 Phase 3 Clinical Trial Starting April 2019

We are enthusiastic about the results of the BAN2401 phase 2 clinical trial for dementia. The study assessed changes from baseline to 18 months in biomarkers measuring the underlying disease pathophysiology, including changes in amyloid accumulated in the brain as measured by amyloid PET (positron emission tomography). The clinical endpoints of Alzheimer’s Disease Composite Score …

BAN2401 Phase 3 Clinical Trial Starting April 2019 Read More »

Translate »